Mental Health

QHSLab, Inc. Publishes Peer-Reviewed Studies Validating Digital Tools for Enhancing Patient Outcomes and Healthcare Efficiency

Recent publications highlight the efficacy of QHSLab's digital assessments in primary care, offering benefits for providers, patients, and practice revenue. ...

Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences, a global leader in the research and intellectual property...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...

NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder

Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is...

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom...

Futures Recovery Healthcare Announces Collaboration with Family Recovery Collective to Expand Support for Families Impacted by Addiction and Mental Health Challenges

TEQUESTA, Fla., May 27, 2025 /PRNewswire/ -- Futures Recovery Healthcare, a leading provider of comprehensive addiction and mental health treatment,...

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders

Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events...

error: Content is protected !!